BioSpace News Archive

Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS) identifying patients with low risk of recurrence independent of traditional clinicopathologic risk factors.

Tiziana Life Sciences Ltd. announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 100,000 common shares at $0.76 per share.

CytoSorbents Corporation announced that the U.S. Army Medical Research Acquisition Activity, with funding from the Combat Casualty Care Research Program, awarded the Company a two-year grant valued at $1,977,024 to optimize development of the HemoDefend-BGA™ adsorber to a fully-finished, commercial device that will be evaluated in a pre-clinical porcine study for safety and efficacy.

Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability (CIN), today announced new data from its lead program, a KIF18A inhibitor, validating its therapeutic approach of synthetic lethality to induce tumor cell death.

Excision BioTherapeutics Inc. announced that Excision Management will present at the following upcoming investor conferences.

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced its participation at several conferences.

NEUWAY Pharma GmbH announced the appointment of Dr Jacques Mallet as an additional independent member of the Advisory Board.

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, announced the presentation of a clinical update on the Human Acellular Vessel for the treatment of vascular trauma.

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced a new clinical site in Australia has been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute to facilitate retina re-attachment surgery.

SCYNEXIS, Inc. announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Annual Global Investment Conference and the Ladenburg Thalmann Annual Healthcare Conference.